Jeff Kindler's Cen­trex­ion re­news bid to make pub­lic de­but

Jef­frey Kindler’s plan to take his biotech — which is de­vel­op­ing a slate of non-opi­oid painkillers — pub­lic, is back on.

The Boston based com­pa­ny, led by …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.